Difficulties designing clinical trials as exemplified by a phase 2 drug evaluation of 5(3,3-bis(2-chloroethyl)-1-triazenol)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea in patients with disseminated breast cancer.
D000505:Alopecia / Q000139:chemically induced; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003510:Cyclohexanes; D004064:Digestive System / Q000187:drug effects; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D009362:Neoplasm Metastasis; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D009607:Nitrosourea Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D010689:Phlebitis / Q000139:chemically induced; D011446:Prospective Studies; D012598:Sclerosis / Q000139:chemically induced; D014652:Vascular Diseases / Q000139:chemically induced
D003510:Cyclohexanes; D007093:Imidazoles; D009588:Nitrogen Mustard Compounds; D009607:Nitrosourea Compounds